WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma
Alexander Rialdi, Mary E. Duffy, Alex P. Scopton, Frank Fonseca, Julia N. Zhao, Megan Schwarz, Pedro Molina-Sánchez, Slim Mzoughi, Elisa Arceci, Jordi Abril‐Fornaguera, Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann, Z.M. Khan, Kevin Mohammed, Xuedi Wang, Xufen Yu, Manikandan Lakshmanan, Ravisankar Rajarethinam, Soo Yong Tan, Jian Jin, Augusto Villanueva, Eleftherios Michailidis, Ype P. de Jong, Charles M. Rice, Ivan Marazzi, Dan Hasson, Josep M. Llovet, Radoslaw M. Sobota, Amaia Lujambio, Ernesto Guccione, Arvin C. Dar (2023). WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nature Cancer, 4(8), pp. 1157-1175, DOI: 10.1038/s43018-023-00609-9.
